cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas (NeckTAR-IN)

Centre Jean Perrin

Status: Enrolling

Conditions: Locally Advanced Head and Neck Carcinoma

Treatments: Biological: blood sampling

Study type: Interventional

Funder types: Other

Identifiers

NCT07178847

2025-A01108-41

Details and patient eligibility

About

The goal of this ancillary clinical trial is to evaluated circulating DNA as a biomarker of residual disease after chemoradiotherapy for locally advanced head and neck squamous cell carninoma.

The main question it aims to answer is :

- Does circulating DNA (cDNA) be able to detect residual disease 3 months after the end of chemoradiotherapy ? Researchers will compare detection of cDNA at 3-months and objective response (clinical and radiological).

Participants will :

• be included in the main study (Neck-TAR)
• have a blood sample 1 and 3-month after the end of treatment

Enrollment: 59 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Selection Criteria:

• Patient included in NeckTAR study
• Written informed consent signed for NeckTAR-IN study
• Affiliation to the French social security system

Trial design

Primary purpose: Screening

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

59 participants in 1 patient group

cDNA detection

Experimental group

Treatment:

Biological: blood sampling